Investigational drug · Phase 2
MT-201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "MT-201"
First trial start
2025
Jun 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Inflammatory Bowel Disease (IBD)
- Ulcerative Colitis (UC)
- Crohn's Disease
Approved drugs for the same conditions: Crohn's disease · Ulcerative colitis · Immunology and inflammation · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MT-201" as an intervention, largest first.
Mirador Therapeutics, Inc.Industry
NCT07113522 · 140 participants (planned) · Start Jun 26, 2025 · Primary completion Apr 30, 2027
Drug: MT-501; MT-201 · For: Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC); Crohn's Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; Sun City, Arizona · 66 sites in all
Mirador Therapeutics, Inc.Industry
NCT07219368 · 56 participants · Start Oct 8, 2025 · Primary completion Oct 20, 2026
Drug: MT-201; Placebo · For: Healthy Volunteer
Sites: San Diego, California
Amgen Research (Munich) GmbHAmgen (AMGN)
NCT00866944 · 35 participants · Start Mar 2009 · Primary completion Jul 2011
Drug: Adecatumumab; Adecatumumab and FOLFOX and 1 more · For: Liver Metastases; Colorectal Cancer
Sites: Strasbourg, France; Augsburg, Germany; Bamberg, Germany · 16 sites in all
Mirador Therapeutics, Inc.Industry
NCT07776782 · 25 participants (planned) · Start Jul 16, 2026 · Primary completion Nov 12, 2026
Drug: MT-201 · For: Healthy Volunteer
Sites: San Diego, California
Michael GunnAcademic, hospital or other
NCT04741984 · 0 participants · Start Aug 2023 · Primary completion May 2025
Drug: MT-201-GBM monocyte vaccine · For: Glioblastoma; Glioma, Malignant
Newest research
PubMed records naming it or its code names, newest first.
- Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial.
Meinel TR, Kaesmacher J, Buetikofer L, et al. · J Neurointerv Surg 2023
- [Detection of hepatic micrometastases in the context of adjuvant chemotherapy and surgery for hepatic metastases].
Schimanski CC, Möhler M, Zimmermann T, et al. · Dtsch Med Wochenschr 2010
- Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking.
Teesson M, Havard A, Fairbairn S, et al. · Drug Alcohol Depend 2005
- Attempted suicide among entrants to three treatment modalities for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and risk factors.
Darke S, Ross J, Lynskey M, et al. · Drug Alcohol Depend 2004
Also in development for Inflammatory Bowel Disease (IBD)
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- HW201877Phase 21 trial
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Inflammatory Bowel Disease (IBD)
- MT-501Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.